Quintiles Expects Expanded Services Contribution To CSO To Be 50% By 2005
Quintiles' expanded non-traditional services will account for roughly 50% of the company's contract sales revenues by the end of 2005 following a reorganization effort, Quintiles predicts.
You may also be interested in...
Quintiles' stake in nitric oxide-based medicines company NitroMed represents one of two initial co-investments under a strategic alliance with venture capital firm Care Capital.
Quintiles plans to invest $50 mil. to $100 mil. in risk-sharing and other "non-traditional" outsourcing deals over the next several years, CEO Dennis Gillings, PhD, told investors at the company's Investor Day Conference in New York City Nov. 30.
Quintiles will convert all aspects of its drug development process, including clinical trial recruitment and physician payment, into web transactions by 2002, the firm indicated during a Jan. 24 conference call announcing its Internet partnership with Healtheon/WebMD.